SI3143025T1 - Spojine za zdravljenje spinalne mišične atrofije - Google Patents

Spojine za zdravljenje spinalne mišične atrofije

Info

Publication number
SI3143025T1
SI3143025T1 SI201531021T SI201531021T SI3143025T1 SI 3143025 T1 SI3143025 T1 SI 3143025T1 SI 201531021 T SI201531021 T SI 201531021T SI 201531021 T SI201531021 T SI 201531021T SI 3143025 T1 SI3143025 T1 SI 3143025T1
Authority
SI
Slovenia
Prior art keywords
compounds
muscular atrophy
spinal muscular
treating spinal
treating
Prior art date
Application number
SI201531021T
Other languages
English (en)
Inventor
Hasane Ratni
Luke Green
Nikolai A. Naryshkin
Marla L. Weetall
Original Assignee
F. Hoffmann-La Roche Ag
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Ptc Therapeutics, Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of SI3143025T1 publication Critical patent/SI3143025T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
SI201531021T 2014-05-15 2015-05-11 Spojine za zdravljenje spinalne mišične atrofije SI3143025T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
PCT/EP2015/060343 WO2015173181A1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy
EP15721701.9A EP3143025B1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
SI3143025T1 true SI3143025T1 (sl) 2020-01-31

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201531952T SI3663296T1 (sl) 2014-05-15 2015-05-11 Postopek za pripravo spojin, uporabnih za zdravljenje spinalne mišične atrofije
SI201531021T SI3143025T1 (sl) 2014-05-15 2015-05-11 Spojine za zdravljenje spinalne mišične atrofije

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201531952T SI3663296T1 (sl) 2014-05-15 2015-05-11 Postopek za pripravo spojin, uporabnih za zdravljenje spinalne mišične atrofije

Country Status (35)

Country Link
US (1) US9969754B2 (sl)
EP (3) EP3663296B1 (sl)
JP (1) JP6236173B2 (sl)
KR (2) KR102213740B1 (sl)
CN (1) CN106459092B (sl)
AR (1) AR100442A1 (sl)
AU (1) AU2015261046C1 (sl)
CA (1) CA2948561C (sl)
CL (1) CL2016002836A1 (sl)
CR (1) CR20160518A (sl)
DK (1) DK3143025T3 (sl)
EA (2) EA035068B1 (sl)
ES (2) ES2949660T3 (sl)
FR (1) FR21C1039I2 (sl)
HR (2) HRP20230637T1 (sl)
HU (2) HUE046491T2 (sl)
IL (2) IL248653B (sl)
LT (1) LTPA2021010I1 (sl)
MA (2) MA39995B1 (sl)
MX (1) MX371050B (sl)
MY (1) MY174284A (sl)
NL (1) NL301128I2 (sl)
NO (1) NO2021035I1 (sl)
NZ (1) NZ725008A (sl)
PE (1) PE20170128A1 (sl)
PH (1) PH12016502081A1 (sl)
PL (2) PL3143025T3 (sl)
PT (1) PT3143025T (sl)
RS (1) RS59718B1 (sl)
SG (1) SG11201609497TA (sl)
SI (2) SI3663296T1 (sl)
TW (1) TWI667239B (sl)
UA (1) UA119670C2 (sl)
WO (1) WO2015173181A1 (sl)
ZA (1) ZA201607026B (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201813877T4 (tr) 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
WO2016184832A1 (en) 2015-05-20 2016-11-24 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
EA036399B1 (ru) * 2015-11-12 2020-11-06 Ф. Хоффманн-Ля Рош Аг Композиции для лечения спинальной мышечной атрофии
AU2016351919B2 (en) * 2015-11-12 2020-11-12 F. Hoffmann-La Roche Ag Compounds for treating amyotrophic lateral sclerosis
JP6872550B2 (ja) 2015-12-10 2021-05-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 架橋されたピペリジン誘導体
LT3386511T (lt) 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Hantingtono ligos gydymo būdai
CA3043755A1 (en) * 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
MX2019014514A (es) 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
EP3638318A4 (en) 2017-06-14 2021-03-17 PTC Therapeutics, Inc. METHOD OF MODULATION OF RNA SPLICING
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
AU2018337597B2 (en) * 2017-09-22 2021-03-25 F. Hoffmann-La Roche Ag Process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7- yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
EP3691647A1 (en) 2017-10-03 2020-08-12 H. Hoffnabb-La Roche Ag New treatment of sma
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
CN113039188A (zh) 2018-10-19 2021-06-25 豪夫迈·罗氏有限公司 新型吡啶并[1,2-a]嘧啶-4-酮衍生物、其制剂及制备方法
EP3982970A1 (en) 2019-06-12 2022-04-20 F. Hoffmann-La Roche AG New treatment of sma
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
IL305203A (en) 2021-03-17 2023-10-01 Hoffmann La Roche New histories of thiazolopyrimidines
EP4308577A1 (en) * 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
WO2022194909A2 (en) 2021-03-18 2022-09-22 F. Hoffmann-La Roche Ag Novel process
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
WO2023202501A1 (zh) * 2022-04-18 2023-10-26 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719193T2 (de) * 1996-08-06 2003-09-25 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
AU2008304231A1 (en) 2007-09-27 2009-04-02 Albany Molecular Research, Inc. Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US8633019B2 (en) * 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) 2008-07-28 2010-02-08 신호열 마우스
WO2010019236A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Methods for treating spinal muscular atrophy
US8126566B2 (en) * 2008-08-14 2012-02-28 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
MX352861B (es) * 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
TR201813877T4 (tr) * 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EP2872493B1 (en) 2012-07-13 2018-11-14 Indiana University Research and Technology Corporation 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy
EA036399B1 (ru) 2015-11-12 2020-11-06 Ф. Хоффманн-Ля Рош Аг Композиции для лечения спинальной мышечной атрофии

Also Published As

Publication number Publication date
SI3663296T1 (sl) 2023-08-31
KR20210014219A (ko) 2021-02-08
HUE046491T2 (hu) 2020-03-30
PE20170128A1 (es) 2017-03-16
PT3143025T (pt) 2019-12-03
EP4241772A2 (en) 2023-09-13
BR112016026205A8 (pt) 2021-07-20
US9969754B2 (en) 2018-05-15
NL301128I2 (nl) 2021-10-25
CR20160518A (es) 2017-02-21
JP2017515863A (ja) 2017-06-15
MX371050B (es) 2020-01-14
NL301128I1 (sl) 2021-09-22
IL248653B (en) 2019-11-28
CN106459092B (zh) 2019-10-15
EP3663296A1 (en) 2020-06-10
EA202090486A3 (ru) 2020-08-31
US20170197990A1 (en) 2017-07-13
CA2948561C (en) 2019-10-22
WO2015173181A1 (en) 2015-11-19
MA39995B1 (fr) 2019-11-29
AR100442A1 (es) 2016-10-05
EA201692280A1 (ru) 2018-07-31
AU2015261046C1 (en) 2019-07-25
NZ725008A (en) 2019-11-29
FR21C1039I1 (sl) 2021-10-15
HUS2100037I1 (hu) 2021-10-28
AU2015261046A1 (en) 2016-10-27
PH12016502081A1 (en) 2017-01-09
IL248653A0 (en) 2017-01-31
MY174284A (en) 2020-04-01
BR112016026205A2 (pt) 2017-08-15
SG11201609497TA (en) 2016-12-29
EP3143025B1 (en) 2019-10-09
NO2021035I1 (no) 2021-09-10
MA51988A (fr) 2021-01-20
LTPA2021010I1 (sl) 2021-10-11
TW201609738A (zh) 2016-03-16
CN106459092A (zh) 2017-02-22
EA035068B1 (ru) 2020-04-23
EP4241772A3 (en) 2023-11-15
UA119670C2 (uk) 2019-07-25
CL2016002836A1 (es) 2017-04-21
AU2015261046B2 (en) 2019-04-18
KR102256013B1 (ko) 2021-05-26
KR20170003687A (ko) 2017-01-09
ES2949660T3 (es) 2023-10-02
DK3143025T3 (da) 2019-12-09
MX2016014547A (es) 2017-02-23
IL270027B (en) 2020-08-31
ZA201607026B (en) 2022-05-25
JP6236173B2 (ja) 2017-11-22
KR102213740B1 (ko) 2021-02-09
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
EP3143025A1 (en) 2017-03-22
ES2761423T3 (es) 2020-05-19
EP3663296B1 (en) 2023-05-17
HRP20230637T1 (hr) 2023-09-29
PL3143025T3 (pl) 2020-03-31
FR21C1039I2 (fr) 2022-09-02
CA2948561A1 (en) 2015-11-19
TWI667239B (zh) 2019-08-01
RS59718B1 (sr) 2020-01-31
PL3663296T3 (pl) 2023-08-07

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
HK1256089A1 (zh) 用於治療脊髓性肌萎縮的組合物
HK1215399A1 (zh) 用於治療脊髓性肌萎縮的化合物
HK1246784A1 (zh) 用於治療脊髓性肌萎縮的化合物
HK1258823A1 (zh) 用於治療肌營養不良的方法
HK1231359A1 (zh) 用於畸形矯正的矯形器
HK1244217A1 (zh) 用於治療蛋白質病的方法
EP3354288C0 (en) STERILIZATION DEVICE
IL251790A0 (en) Compounds include thiazole for the treatment of culture diseases
PL3160913T3 (pl) Sposób oczyszczania osadu biologicznego
GB201405132D0 (en) Fixation apparatus
GB201715519D0 (en) Hand treatment apparatus
HK1248130A1 (zh) 用於治療疼痛的組合物
IL231816A0 (en) Devices for the treatment of bone fractures
GB2534681B (en) Treatment apparatus
GB201604658D0 (en) Treatment for pain
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
ZA201800752B (en) Improved prosthesis for osteosynthesis
ZA201607027B (en) Method for treating or enhancing muscle tissue
PL3129031T3 (pl) Kompozycja do terapii zaburzeń żołądkowych
PL3194551T3 (pl) Stała kompozycja do traktowania tekstyliów
GB201507044D0 (en) Waste treatment
GB201505205D0 (en) Treatment for pain
GB201504688D0 (en) Treatment for pain
GB201418676D0 (en) Compounds for use